Literature DB >> 28603722

External beam techniques to boost cervical cancer when brachytherapy is not an option-theories and applications.

Omar Mahmoud1,2, Sarah Kilic2, Atif J Khan1,2, Sushil Beriwal3, William Small4.   

Abstract

The management of locally advanced cervical cancer relies on brachytherapy (BT) as an integral part of the radiotherapy delivery armamentarium. Occasionally, intracavitary BT is neither possible nor available. In these circumstances, post-external beam radiotherapy (EBRT) interstitial brachytherapy and/or hysterectomy may represent viable options that must be adequately executed in a timely manner. However, if these options are not applicable due to patient related or facility related reasons, a formal contingency plan should be in place. Innovative EBRT techniques such as intensity modulated and stereotactic radiotherapy may be considered for patients unable to undergo brachytherapy. Relying on provocative arguments and recent data, this review explores the rationale for and limitations of non-brachytherapy substitutes in that setting aiming to establish a formal process for the optimal execution of this alternative plan.

Entities:  

Keywords:  Cervical cancer; brachytherapy alternative; intensity modulated radiation therapy (IMRT); robotic radiosurgery; stereotactic body radiotherapy (SBRT)

Year:  2017        PMID: 28603722      PMCID: PMC5451624          DOI: 10.21037/atm.2017.03.102

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  79 in total

1.  Fractionated high dose rate versus low dose rate regimens for intracavitary brachytherapy of the cervix. I. General considerations based on radiobiology.

Authors:  D J Brenner; E J Hall
Journal:  Br J Radiol       Date:  1991-02       Impact factor: 3.039

Review 2.  Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule?

Authors:  D G Petereit; R Pearcey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-15       Impact factor: 7.038

3.  American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy.

Authors:  Akila N Viswanathan; Sushil Beriwal; Jennifer F De Los Santos; D Jeffrey Demanes; David Gaffney; Jorgen Hansen; Ellen Jones; Christian Kirisits; Bruce Thomadsen; Beth Erickson
Journal:  Brachytherapy       Date:  2012 Jan-Feb       Impact factor: 2.362

4.  Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial.

Authors:  F D Patel; S C Sharma; P S Negi; S Ghoshal; B D Gupta
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-01-15       Impact factor: 7.038

Review 5.  High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.

Authors:  Xiaohu Wang; Ruifeng Liu; Bin Ma; Kehu Yang; Jinhui Tian; Lei Jiang; Zheng Gang Bai; Xiang Yong Hao; Jun Wang; Jun Li; Shao Liang Sun; Hong Yin
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

Review 6.  Time-dose factors in radiotherapy: a review of the human data.

Authors:  H D Thames; S M Bentzen; I Turesson; M Overgaard; W Van den Bogaert
Journal:  Radiother Oncol       Date:  1990-11       Impact factor: 6.280

7.  Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy.

Authors:  Dietmar Georg; Christian Kirisits; Martin Hillbrand; Johannes Dimopoulos; Richard Pötter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-19       Impact factor: 7.038

8.  Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results.

Authors:  R W Tsang; A W Fyles; P Kirkbride; W Levin; L A Manchul; M F Milosevic; G A Rawlings; D Banerjee; M Pintilie; G D Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-30       Impact factor: 7.038

9.  CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy.

Authors:  Jonathan Andrew Haas; Matthew R Witten; Owen Clancey; Karen Episcopia; Diane Accordino; Eva Chalas
Journal:  Front Oncol       Date:  2012-03-21       Impact factor: 6.244

10.  Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.

Authors:  Alan J Katz; Michael Santoro; Fred Diblasio; Richard Ashley
Journal:  Radiat Oncol       Date:  2013-05-13       Impact factor: 3.481

View more
  5 in total

1.  Stereotactic Body Radiation Therapy Boost in Patients With Cervical Cancer Ineligible for Brachytherapy.

Authors:  Giuseppe Facondo; Gianluca Vullo; Vitaliana DE Sanctis; Maurizio Valeriani; Anna Maria Ascolese; Maria Massaro; Dimitri Anzellini; Mattia Falchetto Osti
Journal:  Cancer Diagn Progn       Date:  2021-05-03

Review 2.  What is the evidence for the clinical value of SBRT in cancer of the cervix?

Authors:  Loreto Yanez; Ana M Ciudad; Minesh P Mehta; Hugo Marsiglia
Journal:  Rep Pract Oncol Radiother       Date:  2018-10-09

3.  Negative impact of the COVID-19 pandemic on the management of cervical cancer patients in Zambia.

Authors:  Dorothy Lombe; Misheck Phiri; Susan Msadabwe
Journal:  Ecancermedicalscience       Date:  2020-07-07

4.  IMRT and brachytherapy comparison in gynaecological cancer treatment: thinking over dosimetry and radiobiology.

Authors:  Valentina Pinzi; Valeria Landoni; Federica Cattani; Roberta Lazzari; Barbara Alicja Jereczek-Fossa; Roberto Orecchia
Journal:  Ecancermedicalscience       Date:  2019-12-17

5.  Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible.

Authors:  Tae Hoon Lee; Changhoon Song; In Ah Kim; Jae-Sung Kim; Yong Beom Kim; Kidong Kim; Jae Hong No; Dong Hoon Suh; Jin-Beom Chung; Keun-Yong Eom
Journal:  Radiat Oncol       Date:  2021-08-12       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.